United Therapeutics Corporation Stock Performance
as on September 18, 2025 at 1:29 am IST
Day's Low
Day's High
$397.97$405.41
1.41%
Downside
0.43%
Upside
52 Week's Low
52 Week's High
$266.98$436.9533.86%
Downside
8.24%
Upside
United Therapeutics Corporation share price movements today
- Previous Close
- $397.97
- Open
- $397.97
- Volume
- 470.1K
- Day's Low - High
- $397.97 - $405.41
- 52 Week Low - High
- $266.98 - $436.95
United Therapeutics Corporation Historical Returns
- 1 Month Return
- + 27.09 %
- 3 Month Return
- + 38.72 %
- 1 Year Return
- + 15.35 %
- 3 Year Return
- + 82.46 %
- 5 Year Return
- 0 %
United Therapeutics Corporation Stock Fundamentals & Key Indicators
Check United Therapeutics Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$18.0B
EPS (TTM)
26.4805
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.10%
PE Ratio (TTM)
15.52
Industry PE ratio
16.65525641025641
P/B Ratio
15.5215
PEG Ratio
1.4347
EBITDA
1.6B
Revenue (TTM)
3.1B
Profit Margin
40.36%
Return On Equity TTM
19.30%
United Therapeutics Corporation Stock Valuation
Track how United Therapeutics Corporation P/E has moved over time to understand its valuation trends.
United Therapeutics Corporation in the last 5 years
Lowest (10.67x)
March 31, 2024
Today (15.52x)
September 17, 2025
Industry (16.66x)
September 17, 2025
Highest (19.96x)
September 30, 2021
Today’s Price to Earnings Ratio: 15.52x
United Therapeutics Corporation vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of United Therapeutics Corporation with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $18.0B | NA | 15.52 | 40.36% | |
| BUY | $44.0B | NA | 21.51 | 13.81% | |
| BUY | $14.0B | 38.31% | 41.69 | 13.88% | |
| BUY | $65.4B | -8.86% | 25.38 | 27.83% |
Stock Returns calculator for United Therapeutics Corporation Stock including INR - Dollar returns
The United Therapeutics Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
United Therapeutics Corporation investment value today
Current value as on today
₹1,21,597
Returns
₹21,597
(+21.6%)
Returns from United Therapeutics Corporation Stock
₹16,999 (+17%)
Dollar Returns*
₹4,598 (+4.6%)
Analyst Recommendation on United Therapeutics Corporation Stock
Based on 22 analysts
81.82%
Buy
13.64%
Hold
4.55%
Sell
Based on 22 analysts, 81.82% of analysts recommend a 'BUY' rating for United Therapeutics Corporation. Average target price of $466.82
United Therapeutics Corporation Share Price Target
Get share price movements and forecasts by analysts on United Therapeutics Corporation.
What analysts predicted
13.53%UPSIDE
Target Price
$466.82
Current Price
$403.67
Analyzed by
22 Analysts
Target
$466.82
United Therapeutics Corporation target price $466.82, a slight upside of 13.53% compared to current price of $403.67. According to 22 analysts rating.
United Therapeutics Corporation Stock's Interest Amongst Investors
Investment in United Therapeutics Corporation Shares on INDmoney has grown by 121.56% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:121.56% versus previous 30 day period
Search interest for United Therapeutics Corporation Stock has increased by 57% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:57% versus previous 30 day period
United Therapeutics Corporation Quarterly Profit & Loss
All numbers in Millions USD
United Therapeutics Corporation Annual Profit & Loss
All numbers in Millions USD
United Therapeutics Corporation Quarterly Cash Flow
All numbers in Millions USD
United Therapeutics Corporation Annual Cash Flow
All numbers in Millions USD
Global Institutional Holdings in United Therapeutics Corporation
United Therapeutics Corporation News & Key Events
Today's Timeline - 03 September
Wed, 03:48 PM
-BTIG analyst maintains Hold rating on UTHR, citing TETON-2 success but warns of market uncertainties.
Insights on United Therapeutics Corporation
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 1 month, UTHR stock has moved up by 26.7%
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, UTHR has outperformed top 5 stocks with highest market-cap in its industry
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 735.9M → 798.6M (in $), with an average increase of 3.9% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Neurocrine Biosciences Inc. has given 17.6% return, outperforming this stock by 1.4%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 322.2M → 309.5M (in $), with an average decrease of 3.9% per quarter
About United Therapeutics Corporation
| Organisation | United Therapeutics Corporation |
| Headquarters | 1000 Spring Street, Silver Spring, MD, United States, 20910 |
| Industry | Health Technology |
| CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
| E-voting on shares | Click here to vote |
Key Management of United Therapeutics Corporation
Name | Title |
|---|---|
Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation |
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO |
Mr. Michael I. Benkowitz | President & COO |
Mr. Dewey Steadman C.F.A. | Head of Investor Relations |
Mr. Patrick Poisson | Executive VP of Technical Operations |
Mr. Gil Golden | Senior VP & Chief Medical Officer |
Mr. James C. Edgemond | CFO & Treasurer |
Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary |
Ms. Holly Hobson | Associate Vice President of Human Resources |
Kevin T. Gray | Senior Vice President of Strategic Operations & Logistics |
FAQs
What is United Therapeutics Corporation share price today?
United Therapeutics Corporation share price today is $403.67 as on at the close of the market. United Therapeutics Corporation share today touched a day high of $405.41 and a low of $397.97.
What is the 52 week high and 52 week low for United Therapeutics Corporation share?
United Therapeutics Corporation share touched a 52 week high of $436.95 on and a 52 week low of $266.98 on . United Therapeutics Corporation stock price today i.e. is closed at $403.67,which is 7.62% down from its 52 week high and 51.20% up from its 52 week low.
What is United Therapeutics Corporation's market capitalisation today?
United Therapeutics Corporation market capitalisation is $0.02T as on .
How to invest in United Therapeutics Corporation Stock (UTHR) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for United Therapeutics Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in United Therapeutics Corporation Shares that will get you 0.0037 shares as per United Therapeutics Corporation share price of $403.67 per share as on September 18, 2025 at 1:29 am IST.
What is the minimum amount required to buy United Therapeutics Corporation Stock (UTHR) from India?
Indian investors can start investing in United Therapeutics Corporation (UTHR) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in United Therapeutics Corporation stock (as per the Rupee-Dollar exchange rate as on ).
Based on United Therapeutics Corporation share’s latest price of $403.67 as on September 18, 2025 at 1:29 am IST, you will get 0.0248 shares of United Therapeutics Corporation. Learn more about
fractional shares .